title: In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.
abstract: Amid calls for physicians to become better stewards of the nation's health care resources, it is important to gain insight into how physicians think about the cost-effectiveness of new treatments. Expensive new cancer treatments that can extend life raise questions about whether physicians are prepared to make "value for money" trade-offs when treating patients. We asked oncologists in the United States and Canada how much benefit, in additional months of life expectancy, a new drug would need to provide to justify its cost and warrant its use in an individual patient. The majority of oncologists agreed that a new cancer treatment that might add a year to a patient's life would be worthwhile if the cost was less than $100,000. But when given a hypothetical case of an individual patient to review, the oncologists also endorsed a hypothetical drug whose cost might be as high as $250,000 per life-year gained. The results show that oncologists are not consistent in deciding how many months an expensive new therapy should extend a person's life before the cost of therapy is justified. Moreover, the benefit that oncologists demand from new treatments in terms of length of survival does not necessarily increase according to the price of the treatment. The findings suggest that policy makers should find ways to improve how physicians are educated on the use of cost-effectiveness information and to influence physician decision making through clinical guidelines that incorporate cost-effectiveness information.
authors.affiliation: Duke University, Durham, North Carolina, USA. peter.ubel@duke.edu
authors.forename: Peter A
authors.initials: PA
authors.lastname: Ubel
authors.forename: Scott R
authors.initials: SR
authors.lastname: Berry
authors.forename: Eric
authors.initials: E
authors.lastname: Nadler
authors.forename: Chaim M
authors.initials: CM
authors.lastname: Bell
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kozminski
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Palmer
authors.forename: William K
authors.initials: WK
authors.lastname: Evans
authors.forename: Elizabeth L
authors.initials: EL
authors.lastname: Strevel
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Neumann
mesh_terms: D000969:Antinematodal Agents / Q000191:economics*; D001291:Attitude of Health Personnel; D002170:Canada; D002755:Choice Behavior; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019538:Health Care Surveys; D006801:Humans; D007600:Judgment; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy*; D010820:Physicians / Q000523:psychology*; D013534:Survival; D014481:United States
chemical_list: D000969:Antinematodal Agents